Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs State Street SPDR S&P Biotech ETF — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.09 (market cap $44.49B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 4.4× State Street SPDR S&P Biotech ETF's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| JEPQ | XBI | |
|---|---|---|
Market Cap | $44.49B | $10.11B |
Volume | 5,681,789 | 12,903,266 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $61.46 | $169.55 |
52-Week Low | $53.77 | $104.99 |
Typical Hold Time | 66 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.93, down 0.55% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's covered-call strategy generates substantial monthly income, with recent dividends ranging from $0.57 to $0.70 per share. Recent news highlights JEPQ's 11% estimated annual yield and its positioning in AI-driven tech stocks, though the strategy limits upside potential during strong market rallies.
JEPQ offers high income generation through its Nasdaq-focused covered-call approach, making it attractive for retirees seeking monthly cash flow. However, the strategy caps appreciation potential and faces volatility sensitivity, requiring proper portfolio sizing. Key risks include market volatility dependence and competitive pressure from similar income ETFs with different tax treatments.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
